Dexcom, a medical device manufacturer that develops continuous glucose monitoring systems, received a warning letter from the FDA regarding manufacturing processes at its facilities in San Diego and ...
Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...
Medical Device Network on MSN6d
Analysts say Dexcom’s FDA warning unlikely to impact 2025 revenueDexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...
Shares of DexCom Inc. slipped 9.15% to $70.72 Monday, on what proved to be an all-around poor trading session for the stock ...
Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...
The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...
Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the positions showed up on publicly available ...
DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback